Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA
20 April 2015
MSD announced that its anti-PD1 immunotherapy pembrolizumab (trade name KEYTRUDA®) has been registered by the Therapeutic Goods Administration (TGA) for the treatment of the most deadly form of skin cancer – advanced metastatic melanoma. Australia is the first country in the world to register KEYTRUDA for the first line treatment of unresectable or metastatic melanoma in adults. This will change the future of treatments for all melanoma patients in Australia.
Associate Professor Georgina Long from Melanoma Institute of Australia (MIA) explained that Australian clinicians and institutes have been involved in the clinical trials of anti-PD1 for over three years.
“We are proud to have been involved in the development of this medicine and that hundreds of Australian patients with advanced melanoma have been treated with pembrolizumab. This drug is being investigated for use in other cancers. It is vital we continue to do research such as this to improve the outcomes for cancer patients.”
MIA and affiliates will continue to lobby on behalf of the Australian community to ensure anti-PD1 is added to the PBS which would make it accessible for all Australians with advanced melanoma without delay.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
The full-day symposium is for participants with an interest in translational research.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.
Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.
Wyong Rugby League Club Group has joined forces with Melanoma Institute Australia to help end melanoma for future generations.
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.